Coenzyme Q10 for Gulf War Illness: A Replication Study

PHASE3RecruitingINTERVENTIONAL
Enrollment

192

Participants

Timeline

Start Date

September 13, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2027

Conditions
Gulf War SyndromePersian Gulf SyndromeMitochondrial Disorder, Respiratory Chain
Interventions
DRUG

PharmaNord Bio-Quinone Active CoQ10 Gold 100mg

"Each participant receives one softgel three times a day. Arm 1 receives one 100mg softgel and two placebo softgels per day.~Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option drug was chosen as the closest permissible option."

DRUG

PharmaNord Placebo

"Each participant receives one softgel three times a day. Arm 3 receives three placebo softgels per day. Supplement is taken orally in divided doses, with the last softgel not close to bedtime.~Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option drug was chosen as the closest permissible option."

DRUG

PharmaNord Bio-Quinone Active CoQ10 Gold 100mg

"Each participant receives one softgel three times a day. Arm 2 receives three 100mg softgels per day. Supplement is taken orally in divided doses, with the last softgel not close to bedtime.~Because of the presence of the IND, the dropdown menu does not allow us to choose dietary supplement. The option drug was chosen as the closest permissible option."

Trial Locations (1)

92093

RECRUITING

UC San Diego, La Jolla

All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

University of California, San Diego

OTHER